Email Address
Please enter your official email address
We notice that your permissions preference cookie is missing. Please enter your email address so we can determine if you need to complete a permission form or verify that you have already completed this form. Receiving permission from our users is an important part of our compliance with international privacy regulations. Your email address will not be shared without your permission. Please refer to our
privacy policy
for information on how we protect your personal information.
Welcome to AdisInsight
We need some information from you before you start using the platform.
This information will allow us to better understand how AdisInsight is being used.
It does not require or replace the individual login accounts that many of you use to save searches and create email alerts.
Protecting your personal information is important.
That is why AdisInsight collects the minimum amount of information necessary to enable functionality, report usage, and contact you with information about AdisInsight.
For further information on how we protect and process your personal information, please refer to our
privacy policy.
Terms of Service
By accessing or using the AdisInsight platform you agree to the terms of use.
Please select terms of use
How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform.
The number of times you access AdisInsight, the number of searches you performed, and the number of profiles you viewed will be provided to your organization both in aggregate with other users and individually by your email address.
You have the right to opt-out of sharing your email address with your organization but doing so may negatively affect your organization’s decision to renew their subscription to AdisInsight. If you opt-out your email will still be collected for registration purposes.
Please choose your email permissions
Get more from AdisInsight
Keep up to date with all things AdisInsight by signing up to receive our product bulletin, which includes related content from Springer Nature such as white papers, product news, industry commentaries, and webinar invites, straight to your inbox. Unsubscription is always possible via email.
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
No
New Molecular Entity
Yes
Highest Development Phases
Research
Cancer; COVID 2019 infections
Most Recent Events
24 Mar 2020
Early research in Cancer (Diagnosis) in USA (Parenteral) before March 2020
24 Mar 2020
Early research in COVID-2019 infections (Diagnosis) in USA (Parenteral) before March 2020
24 Mar 2020
Early research in COVID-2019 infections in USA (Parenteral) before March 2020
Development Overview
Introduction
Technetium 99m labelled ethylenedicysteine (EC) amifostine (99mTc-EC-amifostine), is a theranostic agent, being developed by Cellpoint, for detection and treatment of COVID-2019 infections as well as detection of cancers arising from viral infections by using EC drug conjugate platform. The company has in-licensed the EC platform from the M.D. Anderson Cancer Center, wherein tissue specific ligands or pharmaceutical compounds are linked to cold metals or radioisotopes. Upon targeted delivery in the organ, EC-Amifostine which is an organic thiophosphate with oxygen scavenging activity, metabolised by alkaline phosphatase (ALP) present on neutrophil surface to an active thiol analog, which scavenge free-radicals and stabilise DNA to protect the infected or organs. 99mTc-EC-amifostine can be detected using both PET and SPECT for imaging to assess location and degree of COVID-2019 infection and associated damage as well as follow-up confirmatory imaging to determine post treatment resolution. 99mTc-EC-amifostine can be used to differentiate the extent of tumour progression and the degree of viral infection involvement with tumour proliferation. Amifostine was originally developed by the Southern Research Institute in Birmingham, Alabama, USA. Early-stage development is underway in the US.
Drug Properties & Chemical Synopsis
Route of administration
Parenteral
Formulation
unspecified
Class
Chemoprotectants, Diagnostic conjugates, Organotechnetium compounds, Organothiophosphorus compounds, Radiopharmaceutical diagnostics, Small molecules, Technetium compounds
Early research in Cancer (Diagnosis) in USA (Parenteral) before March 2020
Updated 30 Mar 2020
24 Mar 2020
Phase Change
Early research in COVID-2019 infections (Diagnosis) in USA (Parenteral) before March 2020
Updated 30 Mar 2020
24 Mar 2020
Phase Change
Early research in COVID-2019 infections in USA (Parenteral) before March 2020
Updated 30 Mar 2020
03 Jun 2005
Licensing Status
Cellpoint in-licenses Oligosaccharide Conjugates for dual imaging and radio/chemotherapy from University of Texas M. D. Anderson Cancer Center
Updated 30 Mar 2020
